The De­part­ment of De­fense could un­der­mine FDA, giv­ing the green light for ex­per­i­men­tal prod­ucts

A de­fense bill mak­ing its way through the Sen­ate would give the Pen­ta­gon pow­er to ap­prove new drugs and med­ical de­vices in some emer­gency in­stances, with clear­ance to ig­nore ad­vice from the FDA.

The pro­posed pol­i­cy would give the De­fense De­part­ment un­prece­dent­ed lee­way, thanks to the bill’s vague lan­guage. The con­cept is alarm­ing con­gres­sion­al staff and Health and Hu­man Ser­vices of­fi­cials, ac­cord­ing to Polit­co, who first re­port­ed the news.

Specif­i­cal­ly, the bill gives the Pen­ta­gon au­thor­i­ty to OK the use of ex­per­i­men­tal and un­ap­proved drugs and med­ical de­vices for emer­gency use on mil­i­tary per­son­nel and “in­di­vid­u­als as­so­ci­at­ed with de­ployed mem­bers of the armed forces,” the bill states. The idea is emer­gency use of some prod­ucts could “re­duce deaths and sever­i­ty of in­juries caused by agents of war.”

One way the DoD might flex this new pow­er is to ap­prove the use of prod­ucts like freeze-dried plas­ma to treat mil­i­tary per­son­nel who have suf­fered blood loss on the bat­tle­field. Freeze-dried plas­ma, un­ap­proved for use in the US, is a sta­ble and long-last­ing dry prod­uct that could be kept at room tem­per­a­ture. Use of the prod­uct, it’s thought, could save lives in the field.

Joe Panet­ta

Joe Panet­ta, pres­i­dent and CEO of Cal­i­for­nia’s biotech in­dus­try group Bio­com, tells me he’s not sur­prised by the DoD’s move.

“I think the mil­i­tary has his­tor­i­cal­ly been giv­en unique priv­i­leges in a num­ber of ar­eas out­side of what ap­plies to in­dus­try and the gen­er­al pub­lic,” Panet­ta said in an email. “This sit­u­a­tion is no dif­fer­ent. I know that in­dus­try wants a process that en­sures safe­ty and ef­fi­ca­cy thanks to a stan­dard­ized and uni­ver­sal­ly ac­cept­ed reg­u­la­to­ry process, i.e. FDA … (But) I em­pathize with the fact that FDA nor­mal­ly pro­ceeds at a pace that does not fit the mil­i­tary’s sit­u­a­tion at times.”

Still, con­cerns arise from how broad the lan­guage is in the bill. For in­stance, the phrase “agents of war” is not a le­gal de­f­i­n­i­tion. Politi­co re­ports that it could open the door for the Pen­ta­gon to ap­prove a wide range of prod­ucts and treat­ments.

The bill does spell out two re­quire­ments the DoD has to meet be­fore sign­ing off on an ex­per­i­men­tal treat­ment or de­vice. First, the DoD would cre­ate a new com­mit­tee of health care ex­perts who must rec­om­mend the use of an un­ap­proved prod­uct. Sec­ond, the as­sis­tant sec­re­tary of de­fense for health af­fairs would need to au­tho­rize the prod­uct’s use af­ter con­sult­ing with the FDA.

Panet­ta said he wasn’t sure what oth­er in­dus­try ex­perts might say, but per­son­al­ly he thinks this sort of pro­vi­sion is war­rant­ed.

“I think that if there is an im­mi­nent need for a ther­a­py or de­vice … then they should be al­lowed to do this,” he wrote in the email.

But, Panet­ta has caveats. The DoD should waive all com­pa­ny li­a­bil­i­ty for the prod­uct, and they should have a re­view pro­ce­dure that ad­e­quate­ly eval­u­ates the risk to their per­son­nel, Panet­ta said. He said an at­trac­tive al­ter­na­tive might be to work with the FDA to set up a spe­cial ex­pidit­ed re­view process for these sit­u­a­tions.

The FDA ac­tu­al­ly of­fered such an al­ter­na­tive to the DoD, but the lan­guage wasn’t ac­cept­ed for the bill, ac­cord­ing to Politi­co.

At an event Tues­day, FDA Com­mis­sion­er Scott Got­tlieb said con­trol over med­ical de­vice and drug ap­provals should stay in the hands of the FDA, The Hill re­ports. Still, he said he sup­ports of an ac­cel­er­at­ed ap­proval process for prod­ucts used on the bat­tle­field, and is will­ing to mod­i­fy the lan­guage the agency pro­posed for the DoD’s bill.

“I’m ful­ly com­mit­ted to try­ing to ex­pe­dite prod­ucts for the war fight­er, and … if they pass the lan­guage that has been put for­ward — the al­ter­na­tive lan­guage — we will com­mit to very quick­ly putting in place the im­ple­ment­ing guid­ance to stand up that process,” Got­tlieb said at the event.


Check out the full text of the Na­tion­al De­fense Au­tho­riza­tion Act for Fis­cal Year 2018 bill. Jump to Sec­tion 732 for more on emer­gency use of un­ap­proved prod­ucts.

Roivant par­lays a $450M chunk of eq­ui­ty in biotech buy­out, grab­bing a com­pu­ta­tion­al group to dri­ve dis­cov­ery work

New Roivant CEO Matt Gline has crafted an all-equity upfront deal to buy out a Boston-based biotech that has been toiling for several years now at building a supercomputing-based computational platform to design new drugs. And he’s adding it to the Erector set of science operations that are being built up to support their network of biotech subsidiaries with an eye to growing the pipeline in a play to create a new kind of pharma company.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Tar­get­ing a Po­ten­tial Vul­ner­a­bil­i­ty of Cer­tain Can­cers with DNA Dam­age Re­sponse

Every individual’s DNA is unique, and because of this, every patient responds differently to disease and treatment. It is astonishing how four tiny building blocks of our DNA – A, T, C, G – dictate our health, disease, and how we age.

The tricky thing about DNA is that it is constantly exposed to damage by sources such as ultraviolet light, certain chemicals, toxins, and even natural biochemical processes inside our cells.¹ If ignored, DNA damage will accumulate in replicating cells, giving rise to mutations that can lead to premature aging, cancer, and other diseases.

Ken Frazier, Merck CEO (Bess Adler/Bloomberg via Getty Images)

UP­DAT­ED: Mer­ck takes a swing at the IL-2 puz­zle­box with a $1.85B play for buzzy Pan­dion and its au­toim­mune hope­fuls

When Roger Perlmutter bid farewell to Merck late last year, the drugmaker perhaps best known now for sales giant Keytruda signaled its intent to take a swing at early-stage novelty with the appointment of discovery head Dean Li. Now, Merck is signing a decent-sized check to bring an IL-2 moonshot into the fold.

Merck will shell out roughly $1.85 billion for Pandion Pharmaceuticals, a biotech hoping to gin up regulatory T cells (Tregs) to treat a range of autoimmune disorders, the drugmaker said Thursday.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 102,100+ biopharma pros reading Endpoints daily — and it's free.

Doug Ingram (file photo)

Why not? Sarep­ta’s third Duchenne MD drug sails to ac­cel­er­at­ed ap­proval

Sarepta may be running into some trouble with its next-gen gene therapy approach to Duchenne muscular dystrophy. But when it comes to antisense oligonucleotides, the well-trodden regulatory path is still leading straight to an accelerated approval for casimersen, now christened Amondys 45.

We just have to wait until 2024 to find out if it works.

Amondys 45’s approval was unceremonious, compared to its two older siblings. There was no controversy within the FDA over approving a drug based on a biomarker rather than clinical benefit, setting up a powerful precedent that still haunts acting FDA commissioner Janet Woodcock as biotech insiders weighed her potential permanent appointment; no drama like the FDA issuing a stunning rejection only to reverse its decision and hand out an OK four months later, which got more complicated after the scathing complete response letter was published; no anxious tea leaf reading or heated arguments from drug developers and patient advocates who were tired of having corticosteroids as their loved ones’ only (sometimes expensive) option.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 102,100+ biopharma pros reading Endpoints daily — and it's free.

Fol­low biotechs go­ing pub­lic with the End­points News IPO Track­er

The Endpoints News team is continuing to track IPO filings for 2021, and we’ve designed a new tracker page for the effort.

Check it out here: Biopharma IPOs 2021 from Endpoints News

You’ll be able to find all the biotechs that have filed and priced so far this year, sortable by quarter and listed by newest first. As of the time of publishing on Feb. 25, there have already been 16 biotechs debuting on Nasdaq so far this year, with an additional four having filed their S-1 paperwork.

Covid-19 roundup: Mer­ck­'s $356M sup­ply deal on hold as FDA asks for more da­ta; UK stud­ies of­fer more in­for­ma­tion on ef­fi­ca­cy of Pfiz­er/BioN­Tech vac­cine af­ter one dose

Merck is pushing back plans to supply the US government with a Covid-19 drug after the FDA asked for more data to support an emergency use authorization.

The antibody, MK-7110, had looked promising in a Phase III study conducted by OncoImmune before Merck came along and bought the biotech for $425 million. At the interim analysis, investigators looked at data from 203 patients and concluded that a single dose of the drug cut the risk of death or respiratory failure by more than 50% among severe patients. And those taking the drug had a 60% higher chance of improvement in clinical status compared to placebo.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 102,100+ biopharma pros reading Endpoints daily — and it's free.

CEO Fred Aslan (Artiva)

NK cell ther­a­py play­er Arti­va makes some more noise, pulling in $120M Se­ries B less than a month af­ter Mer­ck deal

Not even one month after Big Pharma took notice of Artiva when Merck signed a collaboration worth nearly $2 billion in milestones, the off-the-shelf NK cell biotech already has its next big fundraise.

Artiva returns from the venture well Friday with a $120 million Series B round, money they will use to get their first program into the clinic and to file INDs for another two candidates. The raise marks the latest development in a rapidly expanding footprint for Artiva, which, in addition to the Merck deal last month, has now raised almost $200 million since its Series A last June.

Fatty liver conceptual image, 3D illustration showing fatty liver silhouette made from micrograph of liver steatosis (Shutterstock)

The path to NASH: un­der­stand­ing the role of se­vere obe­si­ty in a com­plex, mul­ti-sys­tem dis­ease

Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today. Think you have a voice that should be heard? Reach out to senior editors Kyle Blankenship and Amber Tong.

We often think a person’s transition from a healthy to a diseased state is binary. But that’s often not the case. In reality, the onset of a disease is not something that occurs overnight, and the majority lie on a continuum that is impacted by a multitude of factors. Some of these factors are in a patient’s control. Others are not.

This is the case in nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), two of the most complex diseases that “live” on this proverbial continuum. The clinical onset of NAFLD — and ultimately NASH — is a complex process that is closely related to obesity, insulin resistance and impaired adipose tissue metabolism.

Steve Cutler, Icon CEO (Icon)

In the biggest CRO takeover in years, Icon doles out $12B for PRA Health Sci­ences to fo­cus on de­cen­tral­ized clin­i­cal work

Contract research M&A had a healthy run in recent years before recently petering out. But with the market ripe for a big buyout and the Covid-19 pandemic emphasizing the importance of decentralized trials, Wednesday saw a tectonic shift in the CRO world.

Icon, the Dublin-based CRO, will acquire PRA Health Sciences for $12 billion in a move that will shake up the highest rungs of a fragmented market. The merger would combine the 5th- and 6th-largest CROs by 2020 revenue, according to Icon, and the merger will set the newco up to be the second-largest global CRO behind only IQVIA.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 102,100+ biopharma pros reading Endpoints daily — and it's free.